Dr. Jason N. Macklis, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1700 Luther Ln Ste 2200
Park Ridge, IL 60068
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Rush Medical College of Rush University (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 292
Licensed in Illinois since 2013, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Rush Medical College of Rush University
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036133462 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Advocate Lutheran General Hospital Park Ridge, IL
- Advocate Sherman Hospital Elgin, IL
- Advocate Illinois Masonic Medical Center Chicago, IL
- Advocate Condell Medical Center Libertyville, IL
- Advocate Good Shepherd Hospital Barrington, IL
Medical groups
- Advocate Health and Hospitals Corporation (3,118 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 292
- Services billed
- 1,582
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 698 | 181 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 275 | 70 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 134 | 54 |
| Established patient office or other outpatient visit, 40-54 minutes | 99 | 62 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 83 | 74 |
| New patient office or other outpatient visit, 60-74 minutes | 46 | 46 |
| Insertion of needle into vein for collection of blood sample | 24 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 13 |
| Hospital discharge day management, more than 30 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Park Ridge, IL | 146 |
| Prochlorperazine Maleate Other prescribers in Park Ridge, IL | 110 |
| Dexamethasone Other prescribers in Park Ridge, IL | 101 |
| Tagrisso (osimertinib mesylate) | 80 |
| Levothyroxine Sodium Other prescribers in Park Ridge, IL | 70 |
| Prednisone Other prescribers in Park Ridge, IL | 66 |
| Megestrol Acetate Other prescribers in Park Ridge, IL | 43 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Park Ridge, IL | 38 |
| Alecensa (alectinib hcl) | 37 |
| Tramadol Hcl Other prescribers in Park Ridge, IL | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $3,352 in research payments for these studies, mostly to the institutions running them.
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics, Inc. · Recruiting · NCT04613596
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.